The Effect of Administering a Small Dose of Glucose During Cesarean Section - Full Text View

Purpose

The purpose of this study is to investigate the effect of administering a small dose of glucose on the pregnant women and their neonates during cesarean section. We investigate the safety and efficacy of use of a glucose-containing solution for the pregnant women and the neonates.

Condition	Intervention
Cesarean Section	Drug: administer acetate Ringer's solution Drug: acetate Ringer's solution containing no glucose Drug: acetate Ringer's solution containing 1% glucose


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Investigator) Primary Purpose: Treatment
Official Title:	The Effect of Administering a Small Dose of Glucose on the Pregnant Women and Their Neonates During Cesarean Section

Resource links provided by NLM:

MedlinePlus related topics: Cesarean Section

Drug Information available for: Dextrose

U.S. FDA Resources

Further study details as provided by Yoshihito Fujita, MD, Nagoya City University:

Primary Outcome Measures:

The blood glucose concentration in the neonates at one hour of age [ Time Frame: One hour of age ]

Secondary Outcome Measures:

The blood glucose concentration in the neonates at two hour of age [ Time Frame: Two hour of age ]

Other Outcome Measures:

Evidence of clinical complications (especially, low glucose symptoms) [ Time Frame: Within the first 3 days after cesarean section ]


Estimated Enrollment:	40
Study Start Date:	October 2012
Estimated Primary Completion Date:	October 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: acetate Ringer's solution Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml	Drug: administer acetate Ringer's solution During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery. Drug: acetate Ringer's solution containing no glucose
Active Comparator: acetate Ringer's solution with 1% glucose Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)	Drug: administer acetate Ringer's solution During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery. Drug: acetate Ringer's solution containing 1% glucose

Detailed Description:

Rapid infusion of large amount of glucose is associated with fetal hyperglycemia, hyperinsulinemia, and neonatal hypoglycemia. However, the effect of small dose of glucose is unclear. We conducted a pilot study of small dose of glucose. We investigated the effect of a glucose-containing fluid on the blood sugar of the umbilical artery. We found that in the case of no-glucose-containing fluid, there were some cases in which umbilical arterial concentration of glucose was less than 50 mg/dl, which might cause neonatal hypoglycemia. In addition, in the case of 1%-glucose-containing fluid, mean umbilical arterial concentration of glucose was 97 mg/dl.

The purpose of this study is to investigate the effect of administering a small dose of glucose on the pregnant women and their neonates during cesarean section. We investigate the safety and efficacy of use of a glucose-containing solution for the pregnant women and the neonates.

Eligibility


Ages Eligible for Study:	20 Years to 40 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients undergoing cesarean section who met the criteria of the American Society of Anesthesiologists physical status of 1-2

Exclusion Criteria:

ASA physical status >=3, Obesity (BMI>35), Height>=175cm, Weight>=80Kg

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01706341

Contacts


Contact: Yoshihito Fujita, MD. PhD.	+81-52-851-5511 ext 8281	masui@med.nagoya-cu.ac.jp
Contact: Saya Yoshizawa, MD.	+52-851-5511 ext 8281	sayasaya2002@yahoo.co.jp

Locations


Japan
Departiment of Anesthesiology, Nagoya City University Hospital	Recruiting
Nagoya, Japan, 467-8601
Contact: Yoshihito Fujita, MD. PhD. +81-52-851-5511 ext 8281 masui@med.nagoya-cu.ac.jp
Contact: Saya Yoshizawa, MD. +52-851-5511 ext 8281 sayasaya2002@yahoo.co.jp
Principal Investigator: Saya Yoshizawa, MD.

Sponsors and Collaborators

Nagoya City University

Investigators


Study Chair:	Yoshihito Fujita, MD. PhD.	Department of Anesthesiology, Nagoya City Universtiy

More Information


Responsible Party:	Yoshihito Fujita, MD, Associate professor, the department of Anesthesiology, Nagoya City University
ClinicalTrials.gov Identifier:	NCT01706341 History of Changes
Other Study ID Numbers:	NCU-573
Study First Received:	October 8, 2012
Last Updated:	October 11, 2012

Keywords provided by Yoshihito Fujita, MD, Nagoya City University:


cesarean section intravenous fluid a glucose-containing solution fetal hypoglycemia neonatal hypoglycemia

Additional relevant MeSH terms:


Pharmaceutical Solutions

ClinicalTrials.gov processed this record on August 18, 2017